<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2025-684-90</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-2742</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ И МЕТОДИКИ</subject></subj-group></article-categories><title-group><article-title>Analysis of the relationship between migraine and climacteric syndrome in periand postmenopause</article-title><trans-title-group xml:lang="ru"><trans-title>Анализ связи течения мигрени и климактерического синдрома в перии постменопаузе</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-3192-1936</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Климентова</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Klimentova</surname><given-names>D. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Диана Андреевна Климентова - Кафедра нервных болезней Института клинической медицины им. Н.В. Склифосовского.</p><p>119021, Москва, ул. Россолимо, 11, стр. 1</p></bio><bio xml:lang="en"><p>Diana Andreevna Klimentova - Department of Nervous Diseases N.V. Sklifosovsky Institute of Clinical Medicine.</p><p>11, Rossolimo St., Build. 1, Moscow 119021</p></bio><email xlink:type="simple">klimentovadiana23@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3833-532X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Табеева</surname><given-names>Г. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Tabeeva</surname><given-names>G. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра нервных болезней Института клинической медицины им. Н.В. Склифосовского.</p><p>119021, Москва, ул. Россолимо, 11, стр. 1</p></bio><bio xml:lang="en"><p>Department of Nervous Diseases N.V. Sklifosovsky Institute of Clinical Medicine.</p><p>11, Rossolimo St., Build. 1, Moscow 119021</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>20</day><month>12</month><year>2025</year></pub-date><volume>17</volume><issue>6</issue><fpage>84</fpage><lpage>90</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Klimentova D.A., Tabeeva G.R., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Климентова Д.А., Табеева Г.Р.</copyright-holder><copyright-holder xml:lang="en">Klimentova D.A., Tabeeva G.R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/2742">https://nnp.ima-press.net/nnp/article/view/2742</self-uri><abstract><p>A history of migraine is a predictor of more frequent and severe vasomotor symptoms during periand postmenopause.</p><sec><title>Objective</title><p>Objective: to study the connection between migraine and climacteric syndrome (CS) in periand postmenopausal patients.</p></sec><sec><title>Material and methods</title><p>Material and methods. The study included 120 female patients with migraine in periand postmenopause. The patients were divided into two groups: severe climacteric syndrome (CS; n=78) and mild CS (n=42).</p></sec><sec><title>Results</title><p>Results. The risk of chronic migraine, frequent migraine attacks, high pain intensity during attacks, severe impact of headache on quality of life, severe maladjustment of patients with migraine, severe burden of migraine outside attacks, and insufficient response to headache treatment was significantly higher in the severe CS group than in the non-severe group (p&lt;0.05). In the group of patients with severe migraine, the risk of clinically significant anxiety and clinically significant depression was significantly higher than in the group with mild migraine (p&lt;0.05). When constructing a multiple linear regression model, it was found that MIBS-4 scores, mental health and role functioning due to emotional state (SF-36), anxiety and depression (HADS) can predict the Green Climacteric Scale score in patients with migraine in periand postmenopause (F=25.2; Fcrit=2.29; p&lt;0.05).</p></sec><sec><title>Conclusion</title><p>Conclusion. The course of migraine in patients with severe manifestations of CS is less favourable than in patients with mild CS. The course of migraine and the mental status of patients can influence the severity of CS, and vice versa. Further research is needed to identify the causes of the observed phenomena.</p></sec></abstract><trans-abstract xml:lang="ru"><p>Мигрень в анамнезе – предиктор более частого и тяжелого проявления вазомоторных симптомов в перии постменопаузе.</p><p>Цель исследования – изучение связи между течением мигрени и КС у пациенток в перии постменопаузе.</p><sec><title>Материал и методы</title><p>Материал и методы. В исследование включены 120 пациенток с мигренью в перии постменопаузе. Пациентки были разделены на две группы: тяжелое течение климактерического синдрома (КС; n=78) и нетяжелое течение КС (n=42).</p></sec><sec><title>Результаты</title><p>Результаты. Риск хронической мигрени, частых приступов мигрени, высокой интенсивности боли при приступах, тяжелого влияния головной боли на качество жизни, тяжелой дезадаптации пациенток с мигренью, тяжелого бремени мигрени вне приступов, недостаточного ответа на лечение головной боли оказался значимо выше в группе тяжелого течения КС, чем при его нетяжелом течении (p&lt;0,05). В группе пациенток с тяжелым течением КС риск клинически выраженной тревоги и клинически выраженной депрессии оказался значимо выше, чем в группе нетяжелого течения КС (p&lt;0,05). При построении модели множественной линейной регрессии установлено, что показатели MIBS-4, психического здоровья и ролевого функционирования, обусловленного эмоциональным состоянием (SF-36), тревоги и депрессии (HADS) могут предсказывать значение по шкале Грина у пациенток с мигренью в перии постменопаузе (F=25,2; Fкрит=2,29; p&lt;0,05).</p></sec><sec><title>Заключение</title><p>Заключение. Течение мигрени у пациенток с тяжелыми проявлениями КС менее благоприятно, чем у пациенток с нетяжелым КС.</p><p>Течение мигрени и психический статус пациенток могут влиять на тяжесть течения КС, и наоборот. Для выявления причин наблюдаемых явлений требуются дальнейшие исследования.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>мигрень</kwd><kwd>климактерический синдром</kwd><kwd>перименопауза</kwd><kwd>постменопауза</kwd><kwd>вазомоторные симптомы</kwd><kwd>тревога</kwd><kwd>депрессия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>migraine</kwd><kwd>climacteric syndrome</kwd><kwd>perimenopause</kwd><kwd>postmenopause</kwd><kwd>vasomotor symptoms</kwd><kwd>anxiety</kwd><kwd>depression</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование не имело спонсорской поддержки</funding-statement><funding-statement xml:lang="en">The investigation has not been sponsored</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Менопауза и климактерическое состояние у женщины: клинические рекомендации. Российское общество акушеров-гинекологов. Москва: Министерство здравоохранения Российской Федерации; 2025. ID: 117_3</mixed-citation><mixed-citation xml:lang="en">Menopause and climacteric state in women: clinical guidelines. Russian Society of Obstetricians and Gynecologists. Moscow: Ministry of Health of the Russian Federation; 2025. ID: 117_3 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Lee E, Anselmo M, Tahsin CT, et al. Vasomotor symptoms of menopause, autonomic dysfunction, and cardiovascular disease. Am J Physiol Heart Circ Physiol. 2022;323(6):H1270H1280. doi: 10.1152/ajpheart.00477.2022</mixed-citation><mixed-citation xml:lang="en">Lee E, Anselmo M, Tahsin CT, et al. Vasomotor symptoms of menopause, autonomic dysfunction, and cardiovascular disease. Am J Physiol Heart Circ Physiol. 2022;323(6):H1270H1280. doi: 10.1152/ajpheart.00477.2022</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Waliszewska-Prosol M, Grandi G, Ornello R, et al. Menopause, perimenopause, and migraine: Understanding the intersections and implications for treatment. Neurol Ther. 2025;14(3):665-80. doi: 10.1007/s40120-025-00720-2</mixed-citation><mixed-citation xml:lang="en">Waliszewska-Prosol M, Grandi G, Ornello R, et al. Menopause, perimenopause, and migraine: Understanding the intersections and implications for treatment. Neurol Ther. 2025;14(3):665-80. doi: 10.1007/s40120-025-00720-2</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Gupta S, Villalon CM, Mehrotra S, et al. Female sex hormones and rat dural vasodilatation to CGRP, periarterial electrical stimulation and capsaicin. Headache. 2007;47(2):225-35. doi: 10.1111/j.1526-4610.2006.00526.x</mixed-citation><mixed-citation xml:lang="en">Gupta S, Villalon CM, Mehrotra S, et al. Female sex hormones and rat dural vasodilatation to CGRP, periarterial electrical stimulation and capsaicin. Headache. 2007;47(2):225-35. doi: 10.1111/j.1526-4610.2006.00526.x</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Guo JQ, Deng HH, Bo X, Yang XS. Involvement of BDNF/TrkB and ERK/CREB axes in nitroglycerin-induced rat migraine and effects of estrogen on these signals in the migraine. Biol Open. 2017;6(1):8-16. doi: 10.1242/bio.021022</mixed-citation><mixed-citation xml:lang="en">Guo JQ, Deng HH, Bo X, Yang XS. Involvement of BDNF/TrkB and ERK/CREB axes in nitroglycerin-induced rat migraine and effects of estrogen on these signals in the migraine. Biol Open. 2017;6(1):8-16. doi: 10.1242/bio.021022</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Martin VT, Pavlovic J, Fanning KM, et al. Perimenopause and menopause are associated with high frequency headache in women with migraine: results of the American Migraine Prevalence and Prevention Study. Headache. 2016:56(2):292-305. doi: 10.1111/head.12763</mixed-citation><mixed-citation xml:lang="en">Martin VT, Pavlovic J, Fanning KM, et al. Perimenopause and menopause are associated with high frequency headache in women with migraine: results of the American Migraine Prevalence and Prevention Study. Headache. 2016:56(2):292-305. doi: 10.1111/head.12763</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ornello R, Caponnetto V, Frattale I, Sacco S. Patterns of Migraine in Postmenopausal Women: A Systematic Review. Neuropsychiatr Dis Treat. 2021;17:859-71. doi: 10.2147/NDT.S285863</mixed-citation><mixed-citation xml:lang="en">Ornello R, Caponnetto V, Frattale I, Sacco S. Patterns of Migraine in Postmenopausal Women: A Systematic Review. Neuropsychiatr Dis Treat. 2021;17:859-71. doi: 10.2147/NDT.S285863</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Saffari TM, Kavanagh K, Ormseth B, et al. Severe obesity is associated with increased migraine severity and frequency: A retrospective cohort study. J Clin Neurosci. 2023;115:8-13. doi: 10.1016/j.jocn.2023.07.007</mixed-citation><mixed-citation xml:lang="en">Saffari TM, Kavanagh K, Ormseth B, et al. Severe obesity is associated with increased migraine severity and frequency: A retrospective cohort study. J Clin Neurosci. 2023;115:8-13. doi: 10.1016/j.jocn.2023.07.007</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Maleki N, Cheng YC, Tu Y, Locascio JJ. Longitudinal course of vasomotor symptoms in perimenopausal migraineurs. Ann Neurol. 2019;85(6):865-74. doi: 10.1002/ana.25476</mixed-citation><mixed-citation xml:lang="en">Maleki N, Cheng YC, Tu Y, Locascio JJ. Longitudinal course of vasomotor symptoms in perimenopausal migraineurs. Ann Neurol. 2019;85(6):865-74. doi: 10.1002/ana.25476</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Sabia S, Fournier A, Mesrine S, et al. Risk factors for onset of menopausal symptoms: results from a large cohort study. Maturitas. 2008;60(2):108-21. doi: 10.1016/j.maturitas.2008.04.004</mixed-citation><mixed-citation xml:lang="en">Sabia S, Fournier A, Mesrine S, et al. Risk factors for onset of menopausal symptoms: results from a large cohort study. Maturitas. 2008;60(2):108-21. doi: 10.1016/j.maturitas.2008.04.004</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Faubion SS, Smith T, Thielen J, et al. Association of Migraine and Vasomotor Symptoms. Mayo Clin Proc. 2023;98(5):701-12. doi: 10.1016/j.mayocp.2023.01.010</mixed-citation><mixed-citation xml:lang="en">Faubion SS, Smith T, Thielen J, et al. Association of Migraine and Vasomotor Symptoms. Mayo Clin Proc. 2023;98(5):701-12. doi: 10.1016/j.mayocp.2023.01.010</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Crowe HM, Rich-Edwards JW, Rexrode KM, Joffe H. Association of migraine and vasomotor symptom severity and duration among naturally menopausal women in Nurses’ Health Study II. Menopause. 2025. doi: 10.1097/GME.0000000000002615</mixed-citation><mixed-citation xml:lang="en">Crowe HM, Rich-Edwards JW, Rexrode KM, Joffe H. Association of migraine and vasomotor symptom severity and duration among naturally menopausal women in Nurses’ Health Study II. Menopause. 2025. doi: 10.1097/GME.0000000000002615</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Karimi L, Wijeratne T, Crewther SG, et al. The Migraine-Anxiety Comorbidity Among Migraineurs: A Systematic Review. Front Neurol. 2021;11:Art. 613372. doi: 10.3389/fneur.2</mixed-citation><mixed-citation xml:lang="en">Karimi L, Wijeratne T, Crewther SG, et al. The Migraine-Anxiety Comorbidity Among Migraineurs: A Systematic Review. Front Neurol. 2021;11:Art. 613372. doi: 10.3389/fneur.2</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Amiri S, Behnezhad S, Azad E. Migraine headache and depression in adults: A systematic review and meta-analysis. Neuropsychiatry. 2019;33(3):131-40. doi: 10.1007/s40211-018-0299-5</mixed-citation><mixed-citation xml:lang="en">Amiri S, Behnezhad S, Azad E. Migraine headache and depression in adults: A systematic review and meta-analysis. Neuropsychiatry. 2019;33(3):131-40. doi: 10.1007/s40211-018-0299-5</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Xu J, Kong F, Buse DC. Predictors of episodic migraine transformation to chronic migraine: A systematic review and meta-analysis of observational cohort studies. Cephalalgia. 2020;40(5):503-16. doi: 10.1177/0333102419883355</mixed-citation><mixed-citation xml:lang="en">Xu J, Kong F, Buse DC. Predictors of episodic migraine transformation to chronic migraine: A systematic review and meta-analysis of observational cohort studies. Cephalalgia. 2020;40(5):503-16. doi: 10.1177/0333102419883355</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Gibson CJ, Ajmera M, O’Sullivan F, et al. A systematic review of anxiety and depressive symptoms among women experiencing vasomotor symptoms across reproductive stages in the US. Int J Womens Health. 2025;17:537-52. doi: 10.2147/IJWH.S491640</mixed-citation><mixed-citation xml:lang="en">Gibson CJ, Ajmera M, O’Sullivan F, et al. A systematic review of anxiety and depressive symptoms among women experiencing vasomotor symptoms across reproductive stages in the US. Int J Womens Health. 2025;17:537-52. doi: 10.2147/IJWH.S491640</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Alblooshi S, Taylor M, Gill N. Does menopause elevate the risk for developing depression and anxiety? Results from a systematic review. Australas Psychiatry. 2023;31(2):165-73. doi: 10.1177/10398562231165439</mixed-citation><mixed-citation xml:lang="en">Alblooshi S, Taylor M, Gill N. Does menopause elevate the risk for developing depression and anxiety? Results from a systematic review. Australas Psychiatry. 2023;31(2):165-73. doi: 10.1177/10398562231165439</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Министерство здравоохранения Российской Федерации. Клинические рекомендации. Мигрень. Всероссийское общество неврологов, Общероссийская общественная организация «Союз реабилитологов России», Межрегиональная общественная организация «Российское общество по изучению головной боли». 2024. ID: 295_4</mixed-citation><mixed-citation xml:lang="en">Ministry of Health of the Russian Federation. Clinical guidelines. Migraine. All-Russian Society of Neurologists, All-Russian Public Organization "Union of Rehabilitologists of Russia", Interregional Public Organization "Russian Society for the Study of Headache". 2024. ID: 295_4 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Табеева ГР, Артеменко АР, Корешкина МИ и др. Преодолевая барьеры на пути эффективного ведения пациентов с мигренью (заявление экспертной группы по оптимизации помощи пациентам с мигренью). Неврология, нейропсихиатрия, психосоматика. 2025;17(2):4-14. doi: 10.14412/2074-2711-2025-2-4-14</mixed-citation><mixed-citation xml:lang="en">Tabeeva GR, Artemenko AR, Koreshkina MI, et al. Overcoming obstacles to effective treatment of patients with migraine (Statement of the expert group on optimizing treatment of patients with migraine). Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2025;17(2):414 (In Russ.). doi: 10.14412/2074-2711-2025-2-4-14</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Diener HC, Gaul C, Lehmacher W, Weiser T. Aspirin, paracetamol (acetaminophen) and caffeine for the treatment of acute migraine attacks: A systemic review and meta-analysis of randomized placebo-controlled trials. Eur J Neurol. 2022;29(1):350-7. doi: 10.1111/ene.15103</mixed-citation><mixed-citation xml:lang="en">Diener HC, Gaul C, Lehmacher W, Weiser T. Aspirin, paracetamol (acetaminophen) and caffeine for the treatment of acute migraine attacks: A systemic review and meta-analysis of randomized placebo-controlled trials. Eur J Neurol. 2022;29(1):350-7. doi: 10.1111/ene.15103</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Табеева ГР. Рациональный подход к купированию приступов мигрени. Неврология, нейропсихиатрия, психосоматика. 2025;17(2):100-6. doi: 10.14412/2074-2711-2025-2-100-106</mixed-citation><mixed-citation xml:lang="en">Tabeeva GR. Rational approach to migraine attacks relief. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2025;17(2):100-6 (In Russ.). doi: 10.14412/2074-2711-2025-2-100-106</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Pellesi L, Jedie B, Barhum F, et al. Headto-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment. Pain Manag. 2025;15(5):279-84. doi: 10.1080/17581869.2025.2494494</mixed-citation><mixed-citation xml:lang="en">Pellesi L, Jedie B, Barhum F, et al. Headto-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment. Pain Manag. 2025;15(5):279-84. doi: 10.1080/17581869.2025.2494494</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Yang CP, Liang CS, Chang CM, et al. Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis. JAMA Network Open. 2021;4(10):e2128544. doi: 10.1001/jamanetworkopen.2021.28544</mixed-citation><mixed-citation xml:lang="en">Yang CP, Liang CS, Chang CM, et al. Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis. JAMA Network Open. 2021;4(10):e2128544. doi: 10.1001/jamanetworkopen.2021.28544</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Lanteri-Minet M, Ducros A, Francois C, et al. Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data. Cephalalgia. 2022 Dec;42(14):1543-64. doi: 10.1177/03331024221123058</mixed-citation><mixed-citation xml:lang="en">Lanteri-Minet M, Ducros A, Francois C, et al. Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data. Cephalalgia. 2022 Dec;42(14):1543-64. doi: 10.1177/03331024221123058</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Артеменко АР, Абрамов ВГ. Ботулинический токсин типа A (Релатокс) в лечении хронической мигрени у взрослых: результаты мультицентрового простого слепого рандомизированного сравнительного исследования IIIb фазы. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;123(5):89-99. doi: 10.17116/jnevro202312305189</mixed-citation><mixed-citation xml:lang="en">Artemenko AR, Abramov VG. Botulinum toxin type A (Relatox) in the treatment of chronic migraine in adults: results of phase IIIb, randomized, one-blind, multicenter, activecontrolled, parallel-group trial. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(5):89-99 (In Russ.). doi: 10.17116/jnevro202312305189</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Табеева ГР, Косивцова ОВ, Ковальчук НА, Орлюк ТА. Рефрактерная мигрень. Неврология, нейропсихиатрия, психосоматика. 2024;16(2):76-86. doi: 10.14412/2074-2711-2024-2-76-86</mixed-citation><mixed-citation xml:lang="en">Tabeeva GR, Kosivtsova OV, Kovalchuk NA, Orlyuk TA. Refractory migraine. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2024;16(2):7686 (In Russ.). doi: 10.14412/2074-2711-2024-2-76-86</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Diener HC, Dodick DW, Turkel CC, et al. Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. Eur J Neurol. 2014;21(6):851-9. doi: 10.1111/ene.12393</mixed-citation><mixed-citation xml:lang="en">Diener HC, Dodick DW, Turkel CC, et al. Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. Eur J Neurol. 2014;21(6):851-9. doi: 10.1111/ene.12393</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Sevivas H, Fresco P. Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review. Eur J Med Res. 2022;27(1):Art. 86. doi: 10.1186/s40001-022-00716-w</mixed-citation><mixed-citation xml:lang="en">Sevivas H, Fresco P. Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review. Eur J Med Res. 2022;27(1):Art. 86. doi: 10.1186/s40001-022-00716-w</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Vernieri F, Iannone LF, Lo Castro F, et al.; Italian Headache Registry (RICe) Study Group. Effectiveness and tolerability of atogepant in the prevention of migraine: A real life, prospective, multicentric study (the STAR study). Cephalalgia. 2025;45(4):3331024251335927. doi: 10.1177/03331024251335927</mixed-citation><mixed-citation xml:lang="en">Vernieri F, Iannone LF, Lo Castro F, et al.; Italian Headache Registry (RICe) Study Group. Effectiveness and tolerability of atogepant in the prevention of migraine: A real life, prospective, multicentric study (the STAR study). Cephalalgia. 2025;45(4):3331024251335927. doi: 10.1177/03331024251335927</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Hou M, Luo X, He S, et al. Efficacy and safety of atogepant, a small molecule CGRP receptor antagonist, for the preventive treatment of migraine: a systematic review and meta-analysis. J Headache Pain. 2024;25(1):116. doi: 10.1186/s10194-024-01822-2</mixed-citation><mixed-citation xml:lang="en">Hou M, Luo X, He S, et al. Efficacy and safety of atogepant, a small molecule CGRP receptor antagonist, for the preventive treatment of migraine: a systematic review and meta-analysis. J Headache Pain. 2024;25(1):116. doi: 10.1186/s10194-024-01822-2</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Aegidius KL, Zwart JA, Hagen K, et al. Hormone replacement therapy and headache prevalence in postmenopausal women. The Head-HUNT study. Eur J Neurol. 2007;14(1):73-8. doi: 10.1111/j.1468-1331.2006.01557.x</mixed-citation><mixed-citation xml:lang="en">Aegidius KL, Zwart JA, Hagen K, et al. Hormone replacement therapy and headache prevalence in postmenopausal women. The Head-HUNT study. Eur J Neurol. 2007;14(1):73-8. doi: 10.1111/j.1468-1331.2006.01557.x</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Kim S, Lee SB, Hong YJ, et al. The influence of endogenous and exogenous hormonal factors on migraine in spontaneous postmenopausal women: A nationwide population-based study in South Korea. Cephalalgia. 2022;42(4-5):376-84. doi: 10.1177/03331024211044441</mixed-citation><mixed-citation xml:lang="en">Kim S, Lee SB, Hong YJ, et al. The influence of endogenous and exogenous hormonal factors on migraine in spontaneous postmenopausal women: A nationwide population-based study in South Korea. Cephalalgia. 2022;42(4-5):376-84. doi: 10.1177/03331024211044441</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Ripa P, Ornello R, Degan D, et al. Migraine in menopausal women: a systematic review. Int J Women's Health. 2015;7:773-82. doi: 10.2147/IJWH.S70073</mixed-citation><mixed-citation xml:lang="en">Ripa P, Ornello R, Degan D, et al. Migraine in menopausal women: a systematic review. Int J Women's Health. 2015;7:773-82. doi: 10.2147/IJWH.S70073</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Witten T, Staszkiewicz J, Gold L, et al. Nonhormonal Pharmacotherapies for the Treatment of Postmenopausal Vasomotor Symptoms. Cureus. 2024 Jan 17;16(1):e52467. doi: 10.7759/cureus.52467</mixed-citation><mixed-citation xml:lang="en">Witten T, Staszkiewicz J, Gold L, et al. Nonhormonal Pharmacotherapies for the Treatment of Postmenopausal Vasomotor Symptoms. Cureus. 2024 Jan 17;16(1):e52467. doi: 10.7759/cureus.52467</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Chavez MP, Pasqualotto E, Ferreira ROM, et al. Fezolinetant for the treatment of vasomotor symptoms associated with menopause: a meta-analysis. Climacteric. 2024 Jun;27(3):245-54. doi: 10.1080/13697137.2024.2334083</mixed-citation><mixed-citation xml:lang="en">Chavez MP, Pasqualotto E, Ferreira ROM, et al. Fezolinetant for the treatment of vasomotor symptoms associated with menopause: a meta-analysis. Climacteric. 2024 Jun;27(3):245-54. doi: 10.1080/13697137.2024.2334083</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Santoro N, Neal-Perry G, Stute P, et al. Fezolinetant effect on vasomotor symptoms due to menopause in women unsuitable for hormone therapy. Curr Med Res Opin. 2025 Feb;41(2):375-84. doi: 10.1080/03007995.2025.2470752</mixed-citation><mixed-citation xml:lang="en">Santoro N, Neal-Perry G, Stute P, et al. Fezolinetant effect on vasomotor symptoms due to menopause in women unsuitable for hormone therapy. Curr Med Res Opin. 2025 Feb;41(2):375-84. doi: 10.1080/03007995.2025.2470752</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Soong RY, Low CE, Ong V, et al. Exercise Interventions for Depression, Anxiety, and Quality of Life in Older Adults With Cancer: A Systematic Review and MetaAnalysis. JAMA Network Open. 2025;8(2):e2457859. doi: 10.1001/jamanetworkopen.2024.57859</mixed-citation><mixed-citation xml:lang="en">Soong RY, Low CE, Ong V, et al. Exercise Interventions for Depression, Anxiety, and Quality of Life in Older Adults With Cancer: A Systematic Review and MetaAnalysis. JAMA Network Open. 2025;8(2):e2457859. doi: 10.1001/jamanetworkopen.2024.57859</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">La Touche R, Fierro-Marrero J, Sanchez-Ruiz I, et al. Prescription of therapeutic exercise in migraine, an evidence-based clinical practice guideline. J Headache Pain. 2023 Jun 7;24(1):68. doi: 10.1186/s10194-023-01571-8</mixed-citation><mixed-citation xml:lang="en">La Touche R, Fierro-Marrero J, Sanchez-Ruiz I, et al. Prescription of therapeutic exercise in migraine, an evidence-based clinical practice guideline. J Headache Pain. 2023 Jun 7;24(1):68. doi: 10.1186/s10194-023-01571-8</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Thomas A, Daley AJ. Women’s views about physical activity as a treatment for vasomotor menopausal symptoms: a qualitative study. BMC Women’s Health. 2020 Sep 14;20(1):203. doi: 10.1186/s12905-020-01063-w</mixed-citation><mixed-citation xml:lang="en">Thomas A, Daley AJ. Women’s views about physical activity as a treatment for vasomotor menopausal symptoms: a qualitative study. BMC Women’s Health. 2020 Sep 14;20(1):203. doi: 10.1186/s12905-020-01063-w</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
